Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Vernalis PLC Announces Successful Study With CCP-01


Monday, 25 Nov 2013 02:10am EST 

Vernalis PLC:Sees Successful completion of the CCP-01 Pivotal Single Dose comparative bioavailability study.It will now move into a multi-dose comparative bioavailability study and continues in 12 month stability studies. Subject to the successful outcome of these studies, filing of the NDA for CCP-01 with the FDA remains on track to be made in mid-2014. 

Related Company News

Company Quote

1.5685
 --
19 Dec 2014